Parmax Pharma (BOM:540359) Common Stock: ₹0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540359 Parmax Pharma Ltd BOM:540359
42 GF Score
Price ₹132.45
GF Value ₹40.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Parmax Pharma Common Stock?

Parmax Pharma BOM:540359 +0.99% 42 Common Stock is ₹0.0 Mil as of Jun. 2026. GuruFocus rates BOM:540359 with a GF Score™ of 42/100 and a GF Value™ of ₹40.79 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Parmax Pharma's quarterly common stock increased from Dec. 2025 (₹0.0 Mil) to Mar. 2026 (₹44.5 Mil) but then declined from Mar. 2026 (₹44.5 Mil) to Jun. 2026 (₹0.0 Mil).

Parmax Pharma's annual common stock stayed the same from Mar. 2024 (₹44.5 Mil) to Mar. 2025 (₹44.5 Mil) and stayed the same from Mar. 2025 (₹44.5 Mil) to Mar. 2026 (₹44.5 Mil).

Parmax Pharma Common Stock Historical Data

* Premium members only.

The historical data trend for Parmax Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parmax Pharma Common Stock Chart

Parmax Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.51 44.51 44.51 44.51 44.51

Parmax Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 44.51 0.00 44.51 0.00
BOM:540359
42GF Score
Parmax Pharma Ltd BOM:540359
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parmax Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of ₹0.0 Mil mean?
Parmax Pharma (BOM:540359) has a Common Stock of ₹0.0 Mil as of Jun. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Parmax Pharma and its competitors.
Is Parmax Pharma's Common Stock too high?
Parmax Pharma's current Common Stock is ₹0.0 Mil. Overall, Parmax Pharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's Common Stock compare to ZTS?
Parmax Pharma's Common Stock of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Parmax Pharma and its competitors. Parmax Pharma's current Common Stock is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹40.79, compared to a current price of ₹132.45 — trading 224.7% above its estimated fair value. The current Common Stock is ₹0.0 Mil. Parmax Pharma's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current Common Stock is ₹0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Parmax Pharma (BOM:540359) Overvalued in 2026?

Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued. The current stock price of ₹132.45 is trading 224.7% above its estimated GF Value™ of ₹40.79. GuruFocus considers Parmax Pharma to be Significantly Overvalued.

Key valuation signals for BOM:540359:

  • Common Stock: ₹0.0 Mil
  • GF Value™: ₹40.79 vs. price of ₹132.45 (224.7% above fair value)
  • GF Score™: 42/100 with 8 warning signs

No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Parmax Pharma Business Description

Address Rajkot-Gondal National Highway No. 27, Plot No. 20, Survey No. 52, Taluka Kotda Sangani, Hadamtala, Rajkot, GJ, IND, 360 311
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its Core Segments: Anti-infectives, Analgesics & anti-inflammatory, Cardiovascular APIs, General oral formulations (tablets, capsules) Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.
42GF Score

Get the complete analysis for BOM:540359

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹132.45
Price
₹40.79
GF Value